Everest Medicines's revenue for the
six
months ended in Dec. 2023 was HK$128.0 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$137.7 Mil.
Everest Medicines's Revenue per Share for the
six
months ended in Dec. 2023 was HK$0.40.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.43.
The historical data trend for Everest Medicines's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Everest Medicines's Revenue
For the Biotechnology subindustry, Everest Medicines's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's Revenue distribution charts can be found below:
* The bar in red indicates where Everest Medicines's Revenue falls into.
Everest Medicines Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$137.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Everest Medicines Revenue Related Terms
Thank you for viewing the detailed overview of Everest Medicines's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Everest Medicines (HKSE:01952) Business Description
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01952 has been successfully added to your 